![Chris Boshoff: The U.S. FDA granted full approval for our therapy developed with our partner Genmab](https://oncodaily.com/pub/uploads/2023/08/aaa-1-1.png)
Chris Boshoff: The U.S. FDA granted full approval for our therapy developed with our partner Genmab
Chris Boshoff shared a post on LinkedIn:
“Today, the U.S. FDA granted full approval for our therapy for the treatment of recurrent or metastatic Cervical Cancer, developed with our partner Genmab. Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease. This approval reinforces the important role of our medicine for these patients, and represents a significant achievement for this patient community who have long faced limited options.”
Read further.
Source: Chris Boshoff/LinkedIn
Chris is Chief Oncology Officer and Executive Vice President for Pfizer. He leads an end-to-end business organization called the Pfizer Oncology Division, which includes drug discovery, early and late phase clinical development, and commercialization of the company’s Oncology portfolio.